Spots Global Cancer Trial Database for SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Official Title: SARC038: A Phase 2 Study of Regorafenib in Combination With Nivolumab in Patients With Refractory or Recurrent Osteosarcoma
Study ID: NCT04803877
Study Description
Brief Summary: A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Detailed Description: This is a single arm, Simon two-stage historically controlled study to compare the 4 month progression-free survival rate of patients with relapsed/refractory osteosarcoma treated with regorafenib in combination with nivolumab to those who received regorafenib alone (historical control).
Keywords
Eligibility
Minimum Age: 5 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Children's Hospital of Los Angeles, Los Angeles, California, United States
University of Miami, Miami, Florida, United States
Johns Hopkins, Baltimore, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
Cincinnati Children's, Cincinnati, Ohio, United States
Oregon Health and Sciences University, Portland, Oregon, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
